Added to YB: 2026-06-10
Pitch date: 2026-06-07
TMDX [neutral]
TransMedics Group, Inc.
+7.37%
current return
Author Info
The Dutch Investors are a team of four seasoned, passionate inversores uncovering the world's top businesses. They bring you 52 in-depth stock analyses each year! Sign up for the newsletter.
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$2.5B
Pitch Price
$69.19
Price Target
N/A
Dividend
N/A
EV/EBITDA
21.43
P/E
15.94
EV/Sales
4.50
Sector
Health Care Equipment and Supplies
Category
growth
Organs Through a Subscription!? - TransMedics Group, Inc.
TMDX (overview): Only FDA-approved portable warm perfusion platform (heart/lung/liver). Rev grew 70% CAGR to $605.5M FY25. Pivoted to Transplant-as-a-Service (NOP) w/ 22 jets, EU expansion via PAD Aviation/Mercedes. NOP case ~$117-120K vs ~$47-70K disposable. But margins fell 66-70%→59-61%; net debt/EBITDA 0.3→3 in one Q, liabilities $940.8M (+65% YoY). High switching costs; path to $1.2B by 2028 plausible, but capital-heavy model's incentive alignment uncertain.
Read full article (4 min)